Drugs / Vocimagene Amiretrorepvec
Vocimagene Amiretrorepvec
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04089163 | Dec 2019 → Jan 2022 | urinary bladder cancer | Tocagen Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT02598011 | Jan 2017 → Nov 2022 | malignant glioma | Tocagen Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT02576665 | Jul 2016 → May 2019 | colorectal cancer, head and neck cancer, high grade astrocytic tumor, lymphoma +7 | Tocagen Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01985256 | Feb 2014 → Mar 2016 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma | Tocagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01470794 | Feb 2012 → Apr 2016 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma | Tocagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04327011 | Feb 2011 → Dec 2019 | astrocytoma (excluding glioblastoma), glioblastoma | Tocagen Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06504381 | Jan 2025 → Jan 2028 expected | glioblastoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06264388 | May 2024 → May 2034 expected | anaplastic astrocytoma | Ashish Shah | Recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04105374 | Jan 2020 → Nov 2025 | anaplastic astrocytoma, glioblastoma, oligodendroglioma | NRG Oncology | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02414165 | Nov 2015 → May 2019 | anaplastic astrocytoma, glioblastoma | Tocagen Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vocimagene Amiretrorepvec | “Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase” PMID 29762717 ↗ Sep 2018 |
| Known as | DB107-RRV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06504381 ↗ |
| Known as | Toca 511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02576665 ↗ |
| Known as | Vocimagen amiretrorepvec | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108627 ↗ |
| Route | Other | “received Toca 511 injected into the resection cavity wall” PMID 29762717 ↗ Sep 2018 |